item management s discussion and analysis of financial condition and results of operations 
general since commencing operations in  the company has been engaged primarily in the research and development of transdermal drug delivery systems 
the company s revenues have been generated principally by license fees  milestone payments pursuant to various license agreements and interest 
a significant portion of revenues in  however  is attributable to the purchase by the company s licensee partners of transdermal estrogen delivery systems for commercial sale in europe and in anticipation of that product s commercial launch in the united states 
to date  the company s product development efforts have been undertaken independently and pursuant to license agreements with rhone poulenc rorer  inc and or its affiliates rpr and ciba geigy corporation ciba geigy 
under these agreements a license fee was paid upon execution 
all of the agreements provided for the payment of monthly development fees or cost reimbursements for product development and or milestone payments upon achieving certain technical and regulatory goals 
the company s results of operations vary significantly from quarter to quarter and depend  among other factors  on the commercial sale of its products  execution of new product development agreements  the timing of fees and milestone payments made by its licensees  the progress of clinical trials conducted by the company and or its licensees and costs associated with the development of the company s products 
the timing of the company s revenue may not match the timing of the company s associated product development expenses for any particular period 
results of operations compared to total revenues increased approximately from approximately  in to approximately  in the increase in revenues during was primarily a result of the increase in product sales of the company transdermal estrogen delivery system to its licensee partners from  in to  in royalties for product sold to one licensee will be recognized after the product is launched 
license revenues decreased approximately from approximately  in to approximately  in the company believes that license revenues will fluctuate from period to period depending on contributing factors which include  but are not limited to  future success in finalizing new collaborative agreements  timely achievement of milestones and strategic decisions on self funding certain projects 
interest income increased approximately from approximately  in to  in primarily as a result of the investment of the proceeds of the public offering of common stock 
cost of product sold increased from approximately  in to approximately  in the gross margin percentage was in and in these manufacturing costs and attendant gross margins were primarily attributable to expenses incurred in the early stages of manufacturing the transdermal estrogen delivery systems 
research and development expenses increased approximately from approximately  in to approximately  in the increase in research and development expenses was attributable to new product development  manufacturing process engineering and development costs  preproduction start up expense and the hiring of additional staff for new and existing programs 
new product development included the transoral dental anesthetic systems and the transdermal estrogen progestogen combination delivery system 
preproduction start up includes the costs associated with staffing  obtaining regulatory approvals and preparing for product commercialization 
general and administrative expenses increased approximately from approximately  in to approximately  in primarily because of increases in staffing  recruiting expenses and professional fees 
compared to total revenues increased from  in to  in the company s license revenue increased approximately million or in from due to certain milestone payments 
the increase in interest income of approximately  or in was attributable to the investment of the proceeds of the june public offering of common stock 
research and development expenses increased approximately  or due to research activities related to new products such as the transoral dental anesthetic system  the transdermal estrogen progestogen combination delivery system  and the transdermal antifungal delivery system  among others 
the increase in research and development expenses was also attributable to increases in the number of research  development  clinical and regulatory personnel  and preproduction expenses relating to the launch of the estradiol product including materials used in preproduction and training runs to test and validate manufacturing equipment and processes 
the increase in general and administrative expenses of approximately  or was primarily due to increases in staffing 
liquidity and capital resources the company has historically financed its operations through public offerings of common stock  including the exercise of warrants issued in connection with the first such offering  private placements of its equity securities  license and contract revenues  interest income and during the calendar year  through the sale of product 
from its inception through december   the company received net proceeds of approximately  from the sale of equity securities  approximately  from license agreements  approximately  from interest income and approximately  from product sales 
at the end of december  the company had approximately  in cash and securities held to maturity 
the decrease in cash  cash equivalents and securities held to maturity of  during primarily reflects the funding of a net loss of  an increase in inventory of  an increase in accounts receivable of  to support the worldwide launch of the transdermal estrogen replacement system and a  investment in property and equipment 
as of december  the company had no significant commitments for capital expenditures 
the company s future capital requirements depend upon numerous factors  including i the progress of its product development programs  ii the time required to obtain government regulatory approvals of products in development  iii the resources that the company devotes to the development of self funded products  proprietary manufacturing methods  advanced technologies and a marketing and sales administration infrastructure  iv the ability of the company to obtain additional license agreements and to manufacture products pursuant to those agreements and v the demand for its products  if and when approved by regulatory authorities 
the company expects to incur additional costs related to product development activities  increased general and administrative expenses and the completion of its manufacturing facilities 
although the company believes that existing cash  cash equivalents and securities held to maturity  anticipated contract and manufacturing revenues  will be adequate for the foreseeable future  circumstances could arise which may result in a desire to raise additional capital 
there can be no assurance that such capital will be available on acceptable terms  or at all 
new accounting standards in march  the financial accounting standards board fasb issued sfas no 
accounting for the impairment of long lived assets and for long lived assets to be disposed of 
sfas no 
establishes accounting standards for long lived assets  certain identifiable intangibles  and goodwill related to those assets to be held and used and for long lived assets and certain identifiable intangibles to be disposed of 
sfas no 
requires that long lived asets and certain identifiable intangibles to be held and used by an entity be reviewed for impairment whenever events or changes in circumstances indicated that the carrying amount of an asset may not be recoverable 
sfas no 
will apply to noven for the year ended december  management believes that the adoption of this statement will not have a material impact on noven s financial statements 
the fasb has also issued sfas no 
 accounting for stock based compensation 
this statement defines a fair value based method of accounting for an employee stock option 
this statement also permits a company to continue to measure compensation costs for their stock option plan using the intrinsic value based method of accounting prescribed by accounting principles board apb opinion no 
 accounting for stock issued to employees 
sfas no 
requires disclosure of the pro forma net income and earnings per share that would be recorded if the fair value method was utilized 
noven plans to continue to utilize the provisions of apb to account for such compensation costs  and will provide the pro forma disclosures required by sfas in its financial statements 

